Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.42 |
| ▸ | CA2 | P00918 | 13/20 | 0.42 |
| ▸ | CA9 | Q16790 | 9/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA6 | P23280 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28268066 | 0.79 | CA2 (0.45) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL1939429 | 0.79 | CA2 (0.47) | CA1CA2CA9CA5AACHE | |
| SCHEMBL3555914 | 0.76 | CA2 (0.43) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL2588715 | 0.76 | CA2 (0.43) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL731096 | 0.74 | CA2 (0.48) | CA1CA2CA9CA5AACHE | |
| SCHEMBL11257468 | 0.73 | CA1 (0.40) | CA1CA2CA9CA5AACHE | |
| SCHEMBL6368622 | 0.73 | CA1 (0.41) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL2150976 | 0.73 | TSHR (0.59) | CA1CA2CA9CA5AACHE | |
| SCHEMBL1106519 | 0.72 | CA1 (0.53) | CA1CA2CA9CA5AACHE | |
| SCHEMBL30593603 | 0.72 | CA1 (0.53) | CA1CA2CA9CA5AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | CA1 3602/4885CA2 1564/4885CA9 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.